Glenmark Pharmaceuticals received approval to conduct clinical trials on favipiravir, with the company planning to start testing in May on 150 patients in different centres across the country. If successful, industry sources revealed the therapy could be available soon.
Moreover, Strides Pharma Science, who has started exporting favipiravir, is also applying for approval of the therapy. The drugmaker said it is evaluating other antivirals to treat the disease, with reports suggesting that the company has considered remdesivir as part of its antiretroviral therapy programme.
Meanwhile, sources revealed that Dr. Reddy’s Laboratories is close to signing a voluntary licence agreement with Gilead Sciences to manufacture remdesivir for the Indian market.
Other clinical studies to start soon include a government-run trial of Sepsivac and a study conducted by Zydus Cadila of the hepatitis C biosimilar interferon alfa-2b.